Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino Sells 4,000 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $5.10, for a total value of $20,400.00. Following the completion of the sale, the director now directly owns 68,334 shares in the company, valued at approximately $348,503.40. This represents a 5.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Abeona Therapeutics Stock Up 2.1 %

Abeona Therapeutics stock opened at $5.25 on Friday. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $9.01. The stock has a fifty day simple moving average of $5.78 and a two-hundred day simple moving average of $5.71. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market cap of $228.22 million, a price-to-earnings ratio of -1.95 and a beta of 1.46.

Wall Street Analyst Weigh In

ABEO has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. Finally, StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th.

Institutional Investors Weigh In On Abeona Therapeutics

Several large investors have recently bought and sold shares of the business. abrdn plc lifted its stake in Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after acquiring an additional 200,647 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after purchasing an additional 429,456 shares during the last quarter. Jane Street Group LLC bought a new position in Abeona Therapeutics during the third quarter valued at approximately $84,000. Western Standard LLC boosted its holdings in Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after purchasing an additional 110,998 shares during the last quarter. Finally, Rosalind Advisors Inc. grew its position in Abeona Therapeutics by 4.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after purchasing an additional 82,000 shares during the period. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.